Tanveer Tabish

Overview

I was educated at the University of Exeter, and received a PhD (nanomedicine), having worked on graphene-based anti-cancer nanomedicine. After a short spell at UCL working on photonanomedicine for the detection of cancer at early, curable and reversible stage funded by the CRUK, I went to Imperial College London developing plasmonic nanomedicines for disease theranostics. In 2022, I joined the Radcliffe Department of Medicine. 

We interweave the scientific fields of nanomedicince, biomaterials, tissue engineering, bioengineering and biochemistry to develop ‘personalised’ solutions that utilise nanotechnology in treating many diseases such as cancer, wound healing, cardiovascular diseases, and central nervous system disorders. Our research interests include the novel synthesis of two-dimensional graphene-related nanosystems, controlled nanomedicine-based drug delivery platforms and mitochondria-targeted nanoassemblies through sub-cellular recognition processes. In collaboration with international colleagues, Dr. Tabish's research has primarily focussed on evaluating the pre-clinical efficacy of graphene-based nanomedicines in in-vitro, in-vivo and ex-vivo models of cancer and infections (see publications).

Personalised nanomedicine for cardiovascular therapy

Our current work directly tackles a major challenge currently unmet in the clinic with an entirely new way to produce nanodrug excipients. As a BHF Advanced Fellow, my research investigates the role of nitric oxide (NO) in cardiovascular diseases and how endogenous and exogenous sources of NO can be manipulated for the treatment and prevention of cardiovascular diseases in a safe and targeted fashion. It also includes the development of synthetic protocols for the imaging of NO in cells/tissues at the sub-cellular levels. These efforts will move further towards creating pH-sensitive nanomedicines able to 'swim' to a target, using selective permeabilities to control passage of specific cargo. For examples, we work in close collaboration with engineers, chemists, pharmacists, and clinicians to fabricate a novel first in class series of nanomedicines designed specifically to target cell's powerhouse 'mitochondria'. Targeting mitochondria with nanomedicines may represent a significantly important therapeutic target and potentially transform the conventional therapeutic interventions both philosophically and practically. This project builds on my expertise in nanomedicine and allows me to extend my knowledge in nanomedicine to cardiovascular therapeutics, thus opening a new research line for leading my group. 

Our work also involves the design and manufacture of cardiovascular implants using a range of 3D printing and biofabrication processes. 

University of North Carolina, Chapel Hill

University of California, Los Angeles

Technical University Munich (TUM)

University of Exeter Medical School